IP Library Granted Patent US 10,183,976
Granted Patent B2
US 10,183,976 · App. 14/213,924 · Granted Jan 22, 2019

Method for producing factor H from a plasma precipitation fraction

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,183,976
App. No.
14/213,924
Granted
Jan 22, 2019
Kind
B2
Abstract

The present disclosure provides, among other aspects, improved methods for the manufacture of Factor H compositions from plasma precipitation fractions. In some aspects, the methods include an improved process step for extracting Factor H from a plasma precipitate fraction with reduced co-extraction of amidolytic activities. In other aspects, the methods include a heat treatment step for reducing impurities, such as amidolytic enzymes, from a Factor H composition. In yet other aspects, the methods include improved anion exchange, heparin affinity, and/or mixed mode chromatographic enrichment of Factor H. In still other aspects, the improved methods include a combination of the individual improved process steps disclosed herein.

Claims (37)

1. A method for preparing an enriched Factor H composition from plasma, the method comprising the steps:

(A) precipitating Factor H from a Cohn plasma pool or Fraction I supernatant with alcohol, thereby forming a Factor H-precipitate;

(B) suspending the Factor H precipitate in a suspension buffer, thereby forming a Factor H suspension,

(C) contacting the Factor H suspension with finely divided silicon dioxide (SiO 2 );

(D) separating the Factor H suspension into a soluble fraction and an insoluble fraction;

(E) extracting Factor H from the insoluble fraction separated in step (D) with an extraction buffer comprising a conductivity of from 15 mS/cm to 24 mS/cm and a pH of from 4.6 to 5.4, thereby forming a Factor H extract; and

(F) chromatographically enriching the Factor H extract, the enriching comprising:

(1) forming a first Factor H enriched mixture by anion exchange chromatography, comprising:

(i) binding Factor H from the Factor H extract to an anion exchange resin using solution conditions comprising, a conductivity of from about 2 mS/cm to about 5 mS/cm and a pH of about 6.1 to about 6.7; and

(ii) eluting Factor H from the anion exchange resin using solution conditions comprising either:

a) a conductivity of from about 20 mS/cm to about 30 mS/cm and a pH of from about 6.0 to about 7.5, or

b) a conductivity of from about 10 mS/cm to about 20 mS/cm and a pH of from about 7.5 to about 8.5, thereby forming the first Factor H enriched mixture:

(2) forming a second Factor H enriched mixture by heparin affinity chromatography, comprising:

(i) binding Factor H from the first Factor H enriched mixture to a heparin affinity resin using solution conditions comprising a conductivity of from about 7 mS/cm to about 11 mS/cm and a pH of from about 6.9 to about 7.5; and

(ii) eluting Factor H from the heparin affinity resin using solution conditions comprising a conductivity of from about 25 mS/cm to about 35 mS/cm and a pH of from about 7.7 to about 8.3, thereby forming the second Factor H enriched mixture; and

(3) forming a third Factor H enriched mixture by mixed mode resin chromatography, comprising:

(i) binding Factor H from the second Factor H enriched mixture to a mixed mode chromatography resin using solution conditions comprising a conductivity of from about 15 mS/cm to about 40 mS/cm and a pH of from about 6.7 to about 7.9; and

(ii) eluting Factor H from the mixed mode chromatography resin using solution conditions comprising a conductivity of from about 4 mS/cm to about 11 mS/cm and a pH of from about 4.3 to about 5.0, thereby forming the third Factor H enriched mixture.

2. The method of claim 1 , wherein Factor H is precipitated from a Cohn plasma pool in step (A).

3. The method of claim 1 , wherein Factor H is precipitated from a Fraction I supernatant in step (A).

4. The method of claim 1 , wherein precipitating (A) includes incubating the Cohn plasma pool or Fraction I supernatant after addition of alcohol to a final concentration of from 17% to 27% at a pH of from 5.5 to 7.0.

5. The method of claim 4 , wherein the Cohn plasma pool or Fraction I supernatant is incubated after addition of alcohol to a final concentration of from 20% to 25% at a pH of from 6.5 to 7.0.

6. The method of claim 4 , wherein the alcohol is ethanol.

7. The method of claim 6 , wherein the ethanol is denatured ethanol.

8. The method of claim 1 , wherein the Factor H precipitate is suspended in step (B) with a suspension buffer having a pH of from 4.0 to 6.0 and a conductivity of from 0.5 mS/cm to 2.0 mS/cm.

9. The method of claim 1 , wherein the Factor H suspension is contacted in step (C) with from 5 g SiO 2 /kg suspended Factor H precipitate to 200 g SiO 2 /kg suspended Factor H precipitate.

10. The method of claim 1 , wherein the insoluble fraction of the SiO 2 treated Factor H suspension is separated in step (D) by filtration.

11. The method of claim 10 , wherein the filtration in step (D) is performed in a filter press and Factor H is extracted in step (E) by circulating an extraction buffer through the filter press containing the separated insoluble fraction.

12. The method of claim 1 , wherein the extraction buffer has a conductivity of 19±2 mS/cm.

13. The method of claim 1 , wherein the extraction buffer has a pH of 5.0±0.2.

14. The method of claim 1 , further comprising a heat treatment step performed at a temperature of from 60° C. to 75° C. and a pH of from 4.5 to 7.0 for 1 to 3 hours in the presence of from 2.5% to 7.5% of a sugar, a sugar alcohol, or a combination thereof.

15. The method of claim 14 , wherein the sugar, sugar alcohol, or combination thereof is sucrose, glucose, sorbitol, or a combination thereof.

16. The method of claim 14 , wherein the sugar, sugar alcohol, or combination thereof is glucose.

17. The method of claim 1 , wherein the mixed mode resin includes an aliphatic ligand.

18. The method of claim 1 , wherein the mixed mode resin includes an aromatic ligand.

19. The method of claim 1 , further comprising a wash step between the mixed mode binding step (3)(i) and the mixed mode eluting step (3)(ii), the wash step comprising:

washing the bound mixed mode chromatography resin with a wash buffer having a conductivity of from 10 mS/cm to 50 mS/cm and a pH of from 6.2 to 7.3.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036368/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036372/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2014
From: MADLENER, RUTH; TESCHNER, WOLFGANG; SCHWARZ, HANS-PETER; SVATOS, SONIA; PLJEVLJAKOVIC, AZRA; NITSCH, LENA
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 033153/0695 →